Clinical Trial Update: INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease [Phase 1]

View source ↗

Summary

A Phase 1 pediatric trial of INCB18424 (ruxolitinib) in relapsed or refractory solid tumors, leukemia, or myeloproliferative disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms
• Solid Tumors

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Children's Oncology Group | Conditions: Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Status: COMPLETED